{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:16:52Z","timestamp":1791303412588,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Newtone"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Facial repigmentation is the primary outcome measure for most vitiligo trials. The Facial Vitiligo Area Scoring Index (F-VASI) score is often chosen as the primary outcome measure to assess the efficacy of treatments for facial vitiligo. Although useful, this scoring system remains subjective and has several limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the agreement and reliability of an algorithmic method to measure the percentage depigmentation of vitiligo on the face.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a dedicated algorithm called Vitil-IA\u00ae to assess depigmentation on standardized facial ultraviolet (UV) pictures. We then conducted a cross-sectional study using the framework of the ERASE trial (NCT04843059) in 22 consecutive patients attending a tertiary care centre for vitiligo. Depigmentation was analysed before any treatment and, for 7 of them, after 3 and 6\u2005months of narrowband UVB treatment combined with 16\u2005mg methylprednisolone, both used twice weekly. Interoperator and interacquisition repeatability measures were assessed for the algorithm. The results of the algorithmic measurement were then compared with the F-VASI and the percentage of depigmented skin scores assessed by 13 raters, including 7 experts in the grading of vitiligo lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one sets of pictures were analysed with the algorithmic method. Internal validation showed excellent reproducibility, with a variation of &amp;lt; 3%. The percentage of depigmentation assessed by the system showed high agreement with the percentage of depigmentation assessed by raters [mean error (ME) \u201311.94 and mean absolute error (MAE) 12.71 for the nonexpert group; ME 0.43 and MAE 5.57 for the expert group]. The intraclass correlation coefficient (ICC) for F-VASI was 0.45 [95% confidence interval (CI) 0.29\u20130.62] and 0.52 (95% CI 0.37\u20130.68) for nonexperts and experts, respectively. When the results were analysed separately for homogeneous and heterogeneous depigmentation, the ICC for homogeneous depigmentation was 0.47 (95% CI 0.31\u20130.77) and 0.85 (95% CI 0.72\u20130.94) for nonexperts and experts, respectively. When grading heterogeneous depigmentation, the ICC was 0.19 (95% CI 0.05\u20130.43) and 0.38 (95% CI 0.20\u20130.62) for nonexperts and experts, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated that the Vitil-IA algorithm provides a reliable assessment of facial involvement in vitiligo. The study underlines the limitations of the F-VASI score when performed by nonexperts for homogeneous vitiligo depigmentation, and in all raters when depigmentation is heterogeneous.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad304","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T09:50:41Z","timestamp":1692870641000},"page":"62-69","source":"Crossref","is-referenced-by-count":17,"title":["Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm"],"prefix":"10.1093","volume":"190","author":[{"given":"Quentin","family":"Marin Dit Bertoud","sequence":"first","affiliation":[{"name":"Newtone Technologies, Research and Development , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Bertold","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, Henri Mondor University Hospital , Cr\u00e9teil , France"},{"name":"Universit\u00e9 Paris Est (UPEC), EpiDermE Research Unit , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G","family":"Pandya","sequence":"additional","affiliation":[{"name":"Palo Alto Foundation Medical Group , Sunnyvale, CA , USA"},{"name":"Department of Dermatology, University of Texas Southwestern Medical Center , Dallas, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Cherel","sequence":"additional","affiliation":[{"name":"Newtone Technologies, Research and Development , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Castillo Martinez","sequence":"additional","affiliation":[{"name":"Newtone Technologies, Research and Development , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Seguy","sequence":"additional","affiliation":[{"name":"Newtone Technologies, Research and Development , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Andrology and Venereology, Ain Shams University , Cairo , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung\u00a0Min","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea , Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-0815","authenticated-orcid":false,"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Post Graduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wolkerstorfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers , Amsterdam , the\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-0556","authenticated-orcid":false,"given":"Philippe","family":"Bahadoran","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Blaise","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Dugourd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Philippo","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Delaval","sequence":"additional","affiliation":[{"name":"Newtone Technologies, Research and Development , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice , France"},{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, U1065, C3M , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2023122107192728500_ljad304-B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023122107192728500_ljad304-B2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122107192728500_ljad304-B3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjd.15560","article-title":"Factors affecting quality of life in patients with vitiligo: a nationwide study","volume":"178","author":"Bae","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023122107192728500_ljad304-B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjd.21672","article-title":"Impact of nonsegmental vitiligo on patients\u2019 health-related quality of life in the United States","volume":"187","author":"Daniel","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023122107192728500_ljad304-B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.18129","article-title":"The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes","volume":"36","author":"Picardo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122107192728500_ljad304-B6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122107192728500_ljad304-B7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.17013","article-title":"International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation","volume":"180","author":"Eleftheriadou","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023122107192728500_ljad304-B8","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.17652","article-title":"Vitiligo: 30\u2005years to put together the puzzle pieces and to give rise to a new era of therapeutic options","volume":"35","author":"Passeron","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122107192728500_ljad304-B9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jdv.16927","article-title":"Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo","volume":"35","author":"Narayan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122107192728500_ljad304-B10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"key":"2023122107192728500_ljad304-B11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2017.12.070","article-title":"The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo","volume":"79","author":"van Geel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023122107192728500_ljad304-B12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2021.06.880","article-title":"Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index","volume":"86","author":"Bae","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2023122107192728500_ljad304-B13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/pcmr.13056","article-title":"Image analysis systems to calculate the surface area of vitiligo lesions: a systematic review of measurement properties","volume":"35","author":"van Geel","year":"2022","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023122107192728500_ljad304-B14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"2023122107192728500_ljad304-B15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.21246","article-title":"Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo","volume":"187","author":"Merhi","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023122107192728500_ljad304-B16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad304\/51839015\/ljad304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/62\/54716194\/ljad304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/62\/54716194\/ljad304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T02:27:09Z","timestamp":1703125629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/1\/62\/7249913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,24]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad304","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,8,24]]}}}